Sungjoon Park

Sungjoon Park

Auto-generated profile, based on publicly available information

Sungjoon Park

Department of Medicine, University of California, San Diego, La Jolla, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
SPSungjoon Park
Sungjoon Park
ESErica Silva
Erica Silva
ASAkshat Singhal
Akshat Singhal
MKMarcus R. Kelly
Marcus R. Kelly
KLKate Licon
Kate Licon
TITrey Ideker
Trey Ideker
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have revolutionized breast cancer therapy. However, <50% of patients have an objective response, and nearly all patients develop resistance during therapy. To elucidate the underlying mechanisms, we constructed an interpretable deep learning model of the response to palbociclib, a CDK4/6i, based on a reference map of multiprotein assemblies in cancer. The model identifies eight core assemblies that integrate rare and common alterations across 90 genes to stratify palbociclib-sensitive versus palbociclib-resistant cell lines. Predictions translate to patients and patient-derived xenografts, whereas single-gene biomarkers do not. Most predictive assemblies can be shown by CRISPR–Cas9 genetic disruption to regulate the CDK4/6i response. Validated assemblies relate to cell-cycle control, growth factor signaling and a histone regulatory complex that we show promotes S-phase entry through the activation of the histone modifiers KAT6A and TBL1XR1 and the transcription factor RUNX1. This study enables an integrated assessment of how a tumor’s genetic profile modulates CDK4/6i resistance.

16 February 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
XZXiaoyu Zhao
Xiaoyu Zhao
ASAkshat Singhal
Akshat Singhal
SPSungjoon Park
Sungjoon Park
JKJungHo Kong
JungHo Kong
RBRobin Bachelder
Robin Bachelder
TITrey Ideker
Trey Ideker
Rapid proliferation is a hallmark of cancer associated with sensitivity to therapeutics that cause DNA replication stress (RS). Many tumors exhibit drug resistance, however, via molecular pathways that are incompletely understood. Here, we develop an ensemble of predictive models that elucidate how cancer mutations impact the response to common RS-inducing (RSi) agents. The models implement recent advances in deep learning to facilitate multidrug prediction and mechanistic interpretation. Initial studies in tumor cells identify 41 molecular assemblies that integrate alterations in hundreds of genes for accurate drug response prediction. These cover roles in transcription, repair, cell-cycle checkpoints, and growth signaling, of which 30 are shown by loss-of-function genetic screens to regulate drug sensitivity or replication restart. The model translates to cisplatin-treated cervical cancer patients, highlighting an RTK–JAK–STAT assembly governing resistance. This study defines a compendium of mechanisms by which mutations affect therapeutic responses, with implications for precision medicine. Significance: Zhao and colleagues use recent advances in machine learning to study the effects of tumor mutations on the response to common therapeutics that cause RS. The resulting predictive models integrate numerous genetic alterations distributed across a constellation of molecular assemblies, facilitating a quantitative and interpretable assessment of drug response. This article is featured in Selected Articles from This Issue, p. 384

1 May 2024
Verified
Other
Open access
XZXiaoyu Zhao
Xiaoyu Zhao
ASAkshat Singhal
Akshat Singhal
SPSungjoon Park
Sungjoon Park
JKJungHo Kong
JungHo Kong
RBRobin Bachelder
Robin Bachelder
TITrey Ideker
Trey Ideker
Table S2 Odds ratio for 45 drug response predictions with multi-drug model.xlsx

1 March 2024
Verified
Other
Open access
XZXiaoyu Zhao
Xiaoyu Zhao
ASAkshat Singhal
Akshat Singhal
SPSungjoon Park
Sungjoon Park
JKJungHo Kong
JungHo Kong
RBRobin Bachelder
Robin Bachelder
TITrey Ideker
Trey Ideker
Table S2 Odds ratio for 45 drug response predictions with multi-drug model.xlsx

1 March 2024
Verified
Other
Open access
XZXiaoyu Zhao
Xiaoyu Zhao
ASAkshat Singhal
Akshat Singhal
SPSungjoon Park
Sungjoon Park
JKJungHo Kong
JungHo Kong
RBRobin Bachelder
Robin Bachelder
TITrey Ideker
Trey Ideker
Table S4 Assembly enrichment in replication and drug sensitivity screens.xlsx

1 March 2024
Verified
Other
Open access
XZXiaoyu Zhao
Xiaoyu Zhao
ASAkshat Singhal
Akshat Singhal
SPSungjoon Park
Sungjoon Park
JKJungHo Kong
JungHo Kong
RBRobin Bachelder
Robin Bachelder
TITrey Ideker
Trey Ideker
Table S1 Annotation of NeST assembly.xlsx